CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity.
作者信息
Hennessy Sean, Leonard Charles E, Freeman Cristin P, Metlay Joshua P, Chu Xin, Strom Brian L, Bilker Warren B
机构信息
Center for Clinical Epidemiology & Biostatistics and Department of Biostatistics & Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
出版信息
J Clin Pharmacol. 2009 Dec;49(12):1483-7. doi: 10.1177/0091270009343006. Epub 2009 Jul 17.
Abstract
摘要
相似文献
1
CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity.
J Clin Pharmacol. 2009 Dec;49(12):1483-7. doi: 10.1177/0091270009343006. Epub 2009 Jul 17.
2
CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
Pharmacogenet Genomics. 2005 Nov;15(11):779-86. doi: 10.1097/01.fpc.0000174787.92861.91.
3
The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin.
J Clin Psychopharmacol. 2012 Jun;32(3):429-31. doi: 10.1097/JCP.0b013e3182549c0c.
4
Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.
Pharmacogenomics. 2012 Sep;13(12):1339-49. doi: 10.2217/pgs.12.117.
5
Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Br J Clin Pharmacol. 2010 Jan;69(1):27-37. doi: 10.1111/j.1365-2125.2009.03558.x.
6
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
JACC Cardiovasc Interv. 2008 Dec;1(6):620-7. doi: 10.1016/j.jcin.2008.09.008.
7
Clinical pharmacogenetics and potential application in personalized medicine.
Curr Drug Metab. 2008 Oct;9(8):738-84. doi: 10.2174/138920008786049302.
8
[Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Zhonghua Yi Xue Za Zhi. 2004 Oct 17;84(20):1686-9.
9
CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.
J Acquir Immune Defic Syndr. 2010 Jul;54(3):285-9. doi: 10.1097/QAI.0b013e3181bf648a.
10
Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
Pharmacogenomics J. 2013 Aug;13(4):359-61. doi: 10.1038/tpj.2012.19. Epub 2012 May 29.
引用本文的文献
1
Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population.
Bioengineered. 2022 Mar;13(3):7709-7745. doi: 10.1080/21655979.2022.2036916.
2
Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling.
Drugs R D. 2020 Dec;20(4):343-358. doi: 10.1007/s40268-020-00323-2. Epub 2020 Oct 7.
3
Pharmacogenomic considerations for medications in the perioperative setting.
Pharmacogenomics. 2019 Jul;20(11):813-827. doi: 10.2217/pgs-2019-0040.
4
Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists.
J Mol Diagn. 2019 Sep;21(5):746-755. doi: 10.1016/j.jmoldx.2019.04.003. Epub 2019 May 8.
5
Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.
Pharmaceuticals (Basel). 2017 Aug 18;10(3):73. doi: 10.3390/ph10030073.
6
Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.
Drugs R D. 2017 Sep;17(3):341-361. doi: 10.1007/s40268-017-0195-7.
7
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
Pharmacogenomics J. 2016 Jun;16(3):286-92. doi: 10.1038/tpj.2015.45. Epub 2015 Jun 30.
8
PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.
Pharmacogenet Genomics. 2015 Apr;25(4):205-21. doi: 10.1097/FPC.0000000000000118.
9
Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6.
10
PharmGKB summary: phenytoin pathway.
Pharmacogenet Genomics. 2012 Jun;22(6):466-70. doi: 10.1097/FPC.0b013e32834aeedb.
本文引用的文献
1
Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations.
Eur J Pharmacol. 2008 Nov 19;598(1-3):1-8. doi: 10.1016/j.ejphar.2008.09.014. Epub 2008 Sep 22.
2
Several major antiepileptic drugs are substrates for human P-glycoprotein.
Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11.
3
Diagnostic E-codes for commonly used, narrow therapeutic index medications poorly predict adverse drug events.
J Clin Epidemiol. 2008 Jun;61(6):561-71. doi: 10.1016/j.jclinepi.2007.08.003. Epub 2008 Feb 14.
4
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
Neuropharmacology. 2007 Feb;52(2):333-46. doi: 10.1016/j.neuropharm.2006.07.038. Epub 2006 Oct 10.
5
Limited P-glycoprotein mediated efflux for anti-epileptic drugs.
J Drug Target. 2006 Jun;14(5):291-300. doi: 10.1080/10611860600720814.
6
Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach.
J Clin Pharm Ther. 2006 Jun;31(3):275-82. doi: 10.1111/j.1365-2710.2006.00712.x.
7
Medication safety in older adults: home-based practice patterns.
J Am Geriatr Soc. 2005 Jun;53(6):976-82. doi: 10.1111/j.1532-5415.2005.53308.x.
8
Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5507-12. doi: 10.1073/pnas.0407346102. Epub 2005 Apr 1.
9
The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
Pharmacogenomics J. 2001;1(3):204-10. doi: 10.1038/sj.tpj.6500025.
10
Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
Pharmacogenetics. 2001 Dec;11(9):803-8. doi: 10.1097/00008571-200112000-00008.
Zotero 插件